A Study to Evaluate the Efficacy and Safety of GDC-8264 in Preventing Cardiac Surgery-Associated Acute Kidney Injury (AKI) and Major Adverse Kidney Events (MAKE)
Market
0.0%
Details
- Resolved Date
- 3/19/26
- Study Completion
- 3/3/26
- Company
- Genentech, Inc.
- Ticker
- RHHBY
- Type
- Trial Status
- Terminated
- Trial Size
- 67
- Volume
- $0
- NCT
- NCT06602453
- Drug Description
- The aim of this study is to evaluate the efficacy and safety of GDC-8264 compared with placebo in participants undergoing cardiac surgery who are determined to be at moderate to high risk of developing AKI and subsequent MAKE at 90 days after surgery (MAKE90). The study will be performed in two parts- Part 1 and Part 2.
Resolution Evidence
- Outcome
- NO
- Status
- Resolved
- Settlement Date
- 4/1/26 UTC
- Executive Summary
Public readout points negative for this exact Phase 2 trial: Genentech said interim data suggested GDC-8264 was unlikely to show significant clinical benefit, and reporting tied that directly to failure to reach the primary efficacy endpoint. ClinicalTrials.gov also shows the study terminated with no results posted.
Sources
Web Searchfiercebiotech.com3/19/26
Genentech shreds RIPK1 inhibitor from pipeline after early ph. 2 failure
Fierce reports Genentech stopped this Phase 2 study after interim data indicated it was unlikely to demonstrate significant clinical benefit; the primary efficacy endpoint was not expected to be delivered.
View source
ClinicalTrialsclinicaltrials.gov1/6/26
Study Details | NCT06602453 | ClinicalTrials.gov
ClinicalTrials.gov lists NCT06602453 and notes 'No Results Posted'; the study record reflects termination rather than a completed positive readout.
View source
Activity Feed
No activity entries match the current filters for this market.
Model Positions
